The promher study: An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer

Stefania Gori, Alessandro Inno, Elena Fiorio, Jennifer Foglietta, Antonella Ferro, Marcella Gulisano, Graziella Pinotti, Marta Gubiotti, Maria Giovanna Cavazzini, Monica Turazza, Simona Duranti, Valeria De Simone, Laura Iezzi, Giancarlo Bisagni, Simon Spazzapan, Luigi Cavanna, Chiara Saggia, Emilio Bria, Elisabetta Cretella, Patrizia ViciDaniele Santini, Alessandra Fabi, Ornella Garrone, Antonio Frassoldati, Laura Amaducci, Silvana Saracchini, Lucia Evangelisti, Sandro Barni, Teresa Gamucci, Lucia Mentuccia, Lucio Laudadio, Alessandra Zoboli, Fabiana Marchetti, Giuseppe Bogina, Gianluigi Lunardi, Luca Boni

Research output: Contribution to journalArticlepeer-review

Abstract

Background The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients are managed in clinical practice in Italy, which clinical or biological characteristics influenced the choice of adjuvant systemic therapy and the outcome of patients. Methods Data of consecutive patients who underwent surgery from January 2007 to December 2012 for HER2-positive, pT1a-b pN0 M0 breast cancer were retrospectively collected from 28Italian centres. Analysis of contingency tables and multivariate generalized logit models were used to investigate the association between the baseline clinical and biological features and the treatment strategy adopted. Results Among 303 enrolled patients, 204 received adjuvant systemic therapy with trastuzumab, 65 adjuvant systemic therapy without trastuzumab and 34 did not receive adjuvant systemic therapy. At the multivariate analysis age, tumor size, proliferation index and hormone receptor status were significantly associated with the treatment choice. Five-year disease-free survival (DFS) probability was 95%, 94.3% and 69.6% for patients treated with adjuvant systemic therapy and trastuzumab, with adjuvant systemic therapy without trastuzumab and for patients who did not receive adjuvant systemic therapy, respectively (p

Original languageEnglish
Article numbere0136731
JournalPLoS One
Volume10
Issue number9
DOIs
Publication statusPublished - Sep 4 2015

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'The promher study: An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer'. Together they form a unique fingerprint.

Cite this